NervGen Pharma Company Description

NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage.

The company’s lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer’s disease.

It has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage.

The company was incorporated in 2017 and is based in Vancouver, Canada.

NervGen Pharma Corp.

Country	Canada
Founded	2017
Industry	Biotechnology
Sector	Healthcare
Employees	7
CEO	Michael Kelly

Contact Details

Address: 112-970 Burrard Street Vancouver, British Columbia V6Z 2R4 Canada
Phone	778 731 1711
Website	nervgen.com

Stock Details

Ticker Symbol	NGEN
Exchange	TSX Venture Exchange
Fiscal Year	January - December
Reporting Currency	CAD
ISIN Number	CA64082X2032
SIC Code	2834

Key Executives

Name	Position
Michael Kelly	Chief Executive Officer, President and Director
William Joseph Radvak BASc	Co-Founder and Advisor
Dr. Harold Martin Punnett D.M.D.	Co-Founder and Independent Director
William J. Adams C.A., CPA, CA, CPA	Chief Financial Officer and Corporate Secretary
Dr. Daniel D. Mikol M.D., Ph.D.	Chief Medical Officer
Brian McAlister	Co-Founder and Advisor
Dr. Charles V. Olson D.Sc.	Senior Vice President of Technical Operations
Elizabeth Eberhardt B.Sc.	Senior Vice President of Program Management